Clinical Trial Update: A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating sequences of cilta-cabtagene autoleucel and talquetamab in combination with daratumumab, and teclistamab in combination…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carvykti (cilta-cabtagene autoleucel) (cilta-cabtagene autoleucel)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (Darzalex) (daratumumab)
• Revlimid (lenalidomide) (lenalidomide)
• Talquetamab (talquetamab)
• Tecvayli (teclistamab) (teclistamab)
• Velcade (bortezomib) (bortezomib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING